H.C. Wainwright lowers Bicara Therapeutics stock price target to $40 on expenses

Investing.com - H.C. Wainwright reduced its price target on Bicara Therapeutics Inc (NASDAQ:BCAX) to $40.00 from $41.00 on Friday, while maintaining a Buy rating on the stock. The $635 million market cap company has seen its shares decline over 33% year-to-date, though analysts maintain a bullish consensus with price targets ranging from $8 to $48.

The research firm cited higher projected long-term operating expenses as the reason for the slight downward adjustment to its 12-month price target.

Bicara reported a second-quarter 2025 net loss of $0.50 per share, nearly matching H.C. Wainwright’s previous estimate of a $0.51 per share loss. The company posted research and development expenses of $24.8 million and selling, general, and administrative expenses of $7.2 million for the quarter.

The firm now projects a full-year 2025 net loss of $2.27 per share for Bicara, an improvement from its previous estimate of a $2.31 per share loss.

Bicara ended the second quarter with $436.6 million in cash, cash equivalents, and marketable securities, which H.C. Wainwright believes should fund operations into the first half of 2029, extending beyond several major upcoming data catalysts.

In other recent news, Bicara Therapeutics has captured attention with several developments. Piper Sandler has initiated coverage on Bicara Therapeutics with an Overweight rating and set a price target of $36. The firm highlighted a "substantial disconnect" between market perceptions of Bicara’s ficera treatment and the views of key opinion leaders in the medical field. Additionally, Stifel has maintained a Buy rating on Bicara, with a $48 price target, following a detailed review of the company’s Phase 1b data on Squamous Cell Carcinoma of the Head and Neck. The discussions at a recent investor event also explored potential development avenues for Bicara’s lead therapeutic candidate, ficerafusp alfa.

Cantor Fitzgerald also reiterated its Overweight rating on Bicara, expressing confidence in the drug’s potential advantages over competitors. In other company news, Relay Therapeutics appointed Claire Mazumdar, the CEO of Bicara Therapeutics, to its Board of Directors as they prepare for a significant breast cancer trial. Meanwhile, Rice Biotech Launch Pad announced the addition of Carolyn Ng from TPG Life Sciences to its advisory board, expanding its expertise in biotech investments. These updates highlight ongoing strategic moves and positive analyst sentiment surrounding Bicara Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.